RICHMOND, British Columbia, Sept. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
RICHMOND, British Columbia, Sept. 8, 2011 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
